Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Carcinoma, Non-small Cell Lung”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00212043
What this trial is testing

Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma

Who this might be right for
Non Small Cell Lung Cancer
National University Hospital, Singapore 74
Early research (Phase 1)Study completedNCT00022308
What this trial is testing

Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Fox Chase Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02535338
What this trial is testing

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Non-Small Cell Cancer AJCC v7
National Cancer Institute (NCI) 11
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07416058
What this trial is testing

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Who this might be right for
Lung Adenocarcinoma
Guangdong Association of Clinical Trials 61
Not applicableEnded earlyNCT05124743
What this trial is testing

HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

Who this might be right for
Ovarian CancerEndometrial CancerColo-rectal Cancer+3 more
Alaunos Therapeutics 19
Not applicableStudy completedNCT00199615
What this trial is testing

Follow-up of Patients With Curative-intent Surgical Resection for NSCLC

Who this might be right for
Non-small Cell Lung Cancer
University Hospital, Limoges 73
Not applicableStudy completedNCT03859349
What this trial is testing

The Canada Lymph Node Score: A Feasibility Randomized Controlled Trial

Who this might be right for
Non Small Cell Lung Cancer
St. Joseph's Healthcare Hamilton 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT05565378
What this trial is testing

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 351
Testing effectiveness (Phase 2)WithdrawnNCT05757843
What this trial is testing

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Who this might be right for
NSCLC, Stage III
Indiana University
Testing effectiveness (Phase 2)Looking for participantsNCT06660407
What this trial is testing

Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
Mayo Clinic 20
Testing effectiveness (Phase 2)Ended earlyNCT02584634
What this trial is testing

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer 43
Not applicableLooking for participantsNCT07510321
What this trial is testing

FL-261 Imaging for Cancer Diagnosis and Staging

Who this might be right for
Non-Small Cell Lung CancerColorectal CancerHead & Neck Cancer+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 12
Post-approval studies (Phase 4)Not Yet RecruitingNCT06893354
What this trial is testing

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

Who this might be right for
NSCLC
The First Affiliated Hospital of Guangzhou Medical University 20
Testing effectiveness (Phase 2)UnknownNCT03765775
What this trial is testing

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Who this might be right for
CarcinomaNon-small Cell Lung CancerLung Neoplasm
First Hospital of Shijiazhuang City 20
Not applicableStudy completedNCT00540241
What this trial is testing

Performance Status During Treatment With Pemetrexed in Patients With NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 542
Early research (Phase 1)WithdrawnNCT05905341
What this trial is testing

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Who this might be right for
Breast CancerOvarian CancerLiposarcoma+3 more
Pfizer
Testing effectiveness (Phase 2)UnknownNCT04164745
What this trial is testing

Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Peking Union Medical College Hospital 49
Testing effectiveness (Phase 2)Study completedNCT04677595
What this trial is testing

Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals 36
Not applicableLooking for participantsNCT07837739
What this trial is testing

Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Tongji Hospital 100
Testing effectiveness (Phase 2)UnknownNCT01965275
What this trial is testing

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Who this might be right for
Self EfficacyDrug Toxicity
Anhui Medical University 20
Next Page